Sphere Bio enters China market with Redbert Biotechnology distribution deal
Sphere Bio has signed an exclusive distribution agreement with Redbert Biotechnology to expand access to its single-cell analysis and cell therapy platforms in China.
The move marks a key step in the company’s APAC expansion strategy and strengthens its commercial presence in one of the world’s largest life sciences markets.
Based in Beijing, Redbert Biotechnology is a specialist bioprocess distributor with reach across Shanghai, Shenzhen, Chengdu, and other regional hubs. The company will support sales and local deployment of Sphere Bio’s picodroplet-based microfluidic technologies, including the recently launched Cyto-Mine® Chroma multiplexing platform.
To lead local operations, Sphere Bio has appointed Johnathan Fu as China Distribution Manager. Fu brings nearly two decades of experience in laboratory instrumentation sales, having held roles at 10x Genomics, Roche Diagnostics, and Bio-Rad. He will oversee partner enablement and customer success in China and Hong Kong, reporting to Jay Manikandan, VP of Commercial for APAC.
“China’s life sciences sector is growing rapidly, and we see strong demand for next-generation solutions in single-cell analysis and antibody discovery,” said Dale Levitzke, CEO of Sphere Bio. “With Redbert’s local expertise and Johnathan’s leadership, we’re well-positioned to deliver more value to customers and deepen our engagement in the region.”
Redbert serves a broad customer base spanning CDMOs, CROs, academic labs, and biopharma companies. The partnership is expected to improve speed and support for Chinese customers using Sphere Bio’s platforms in cell line development, cell engineering, and therapeutic research.
Wei Zhang, CEO of Redbert Biotechnology, welcomed the collaboration. “We’ve been impressed by Sphere Bio’s technology, particularly the multiplexing and throughput of Cyto-Mine Chroma. We’re excited to bring these capabilities to the Chinese market.”
The partnership is part of Sphere Bio’s broader international growth strategy, with ongoing commercial scale-up across the Asia-Pacific region.




